Skip to content

Clinical trials

Keratoconus trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Keratoconus Clear all

296 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20031
20052
20063
200712
20089
20099
201013
201116
201216
201312
201415
201516
201616
201713
201818
201924
202016
202122
202212
202312
202411
202516
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed132
Unknown status77
Recruiting31
Terminated22
Not yet recruiting11
Active, not recruiting9
Withdrawn7
Enrolling by invitation6
No longer available1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Assiut University11
Cornea and Laser Eye Institute10
Glaukos Corporation8
Democritus University of Thrace7
Oregon Health and Science University6
Shahid Beheshti University of Medical Sciences6
Cxlusa5
Federal University of São Paulo5
Medical University of Vienna5
Zhongshan Ophthalmic Center, Sun Yat-sen University5

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Keratoconus296
Corneal Diseases36
Dilatation, Pathologic23
Eye Diseases10
Corneal Dystrophies, Hereditary8
Dry Eye Syndromes8
Glaucoma7
Corneal Opacity6
Fuchs' Endothelial Dystrophy5
Astigmatism4

Trials

Showing 76 to 100 of 296. Each trial links to its page on Pharma Observatory.

196 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.